| Title |
Results of the ONTARGET and TRANSCEND studies: an update and discussion
|
|---|---|
| Published in |
Vascular Health and Risk Management, December 2008
|
| DOI | 10.2147/vhrm.s3718 |
| Pubmed ID | |
| Authors |
David Fitchett |
| Abstract |
The renin angiotensin aldosterone system (RAAS) plays an important role in the pathophysiology of cardiovascular disease. Angiotensin converting enzyme inhibitors (ACEi) have proven benefit in reducing cardiovascular events in patients at high risk. Angiotensin receptor blockers (ARB) have been demonstrated to have benefit in the management of heart failure and to be non-inferior to ACEi in patients with left ventricular dysfunction after a myocardial infarction (MI). Yet until now, there has been no trial to support the use of the ARB for vascular protection. The ONTARGET study showed that the ARB telmisartan conserved 95% of the vascular protective properties of the ACEi ramipril, given at similar doses to a similar patient group as had been previously shownin the HOPE study to benefit from ACE inhibition with ramipril. The TRANSCEND study in a similar population of patients who were intolerant of ACEi despite the primary endpoint being neutral, showed a trend to a benefit for the combined secondary endpoint of cardiovascular death, MI and stroke, with excellent tolerance of the ARB. The reasons for neutral result of the TRANSCEND study result include an underpowered study, and pre-treatment with a RAAS inhibitor in a high proportion of patients. These studies indicate that an ARB can be used for vascular protection in high risk individuals in the place of an ACEi. However ACEi will probably remain the first choice due to the greater body of supportive evidence. |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Japan | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 70 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 19% |
| Student > Master | 11 | 15% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Bachelor | 7 | 10% |
| Student > Postgraduate | 7 | 10% |
| Other | 15 | 21% |
| Unknown | 12 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 56% |
| Agricultural and Biological Sciences | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Neuroscience | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 15 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 June 2022.
All research outputs
#2,485,648
of 25,374,647 outputs
Outputs from Vascular Health and Risk Management
#67
of 804 outputs
Outputs of similar age
#10,772
of 179,597 outputs
Outputs of similar age from Vascular Health and Risk Management
#3
of 20 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,597 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.